S. Boyce - Concepedia

Concepedia

Author

S. Boyce

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

S Boyce, S. Boyce, Stuart A. J. Boyce

30

Publications

3.4K

Citations

18

H-Index

56

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)MSD (UK) Limited (United Kingdom)Merck Canada Inc. (Canada)Merck (United Kingdom)

SB

About

S. Boyce is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, neuropharmacology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	2K
2	Social Sciences	8	8	605
3	Health Sciences	4	4	587
4	Natural Sciences	1	1	426
5	Anesthesia	1	1	113

S. Boyce

×

21

Publications

3.4K

Citations

18

H-Index

	Year	Citations
Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 Denis Riendeau, M. David Percival, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	2001	456
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Petpiboon Prasit, Z Wang, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryActive Cyclooxygenase-2 InhibitorPharmaceutical ScienceBiochemistry	1999	426
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1999	397
Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein G. R. Dawson, Guy R. Seabrook, Hui Zheng, Neuroscience Synaptic PlasticityCognitive ScienceNeurodegenerative DiseasesAge-related Cognitive Deficitsβ-Amyloid Precursor Protein	1999	358
Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn S. Boyce, A. C. Wyatt, J.K. Webb, Neuropharmacology Motor DysfunctionHealth SciencesSelective Nmda Nr2bPain MedicineNeuroanatomy	1999	336
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor Denis Riendeau, M. David Percival, S. Boyce, British Journal of Pharmacology Pge2 ProductionChemoprevention StrategyImmunologyPharmacotherapyPharmaceutical Chemistry	1997	326
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1995	313
Possible Antimigraine Mechanisms of Action of the 5HT<sub>1F</sub> Receptor Agonist LY334370 Sara L. Shepheard, Lars Edvinsson, M. Cumberbatch, Cephalalgia Pain MedicineAntimigraine EffectAnesthetic MechanismMolecular PainPharmacotherapy	1999	113
Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel Monkeys S. Boyce, N.M.J. Rupniak, M. J. Steventon, Clinical Neuropharmacology	1990	100
Antinociceptive activity of NK<sub>1</sub> receptor antagonists: non‐specific effects of racemic RP67580 N.M.J. Rupniak, S. Boyce, Angela Williams, British Journal of Pharmacology Pain DisordersPain MedicineSynaptic TransmissionImmunologyNeuropathic Pain	1993	93

Page 1